Vonoprazan With Amoxicillin or Amoxicillin and Clarithromycin for the Treatment of Helicobacter pylori Infection

PHARMACODYNAMICS AND PHARMACOKINETICS OF THE POTASSIUM-COMPETITIVE ACID BLOCKER VONOPRAZAN AND THE PROTON PUMP INHIBITOR LANSOPRAZOLE IN U.S. SUBJECTS

(2022) Loren Laine et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Helicobacter pylori Antibiotic Resistance in the United States Between 2011-2021: A Systematic Review and Meta-Analysis

(2022) Jonathan J. C. Ho et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Effectiveness and safety of vonoprazan‐based regimen for Helicobacter pylori eradication: A meta‐analysis of randomized clinical trials

(2022) Chen Yang et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Comparison of Vonoprazan and Amoxicillin Dual Therapy with Standard Triple Therapy with Proton Pump Inhibitor for Helicobacter Pylori eradication: A Randomized Control Trial

(2022) Bader Faiyaz Zuberi et al.   Pakistan Journal of Medical Sciences

Clinical trial: seven‐day vonoprazan‐ versus 14‐day proton pump inhibitor‐based triple therapy for first‐line Helicobacter pylori eradication

(2022) Daphne Ang et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial

(2022) William D. Chey et al.   GASTROENTEROLOGY

The efficacy of vonoprazan combined with different dose amoxicillin on eradication of Helicobacter pylori: an open, multicenter, randomized clinical study

(2022) Yimin Lin et al.   Annals of Translational Medicine

Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis

(2021) Theodore Rokkas et al.   GASTROENTEROLOGY

AGA Clinical Practice Update on the Management of Refractory Helicobacter pylori Infection: Expert Review

(2021) Shailja C. Shah et al.   GASTROENTEROLOGY

Helicobacter pylori infection and antibiotic resistance — from biology to clinical implications

(2021) Evariste Tshibangu-Kabamba et al.   Nature Reviews Gastroenterology & Hepatology

The effect of CYP2C19 gene polymorphism on the eradication rate of Helicobacter pylori by proton pump inhibitors-containing regimens in Asian populations: a meta-analysis

(2021) Juan Fu et al.   PHARMACOGENOMICS

The Effect of Food on the Pharmacokinetics of the Potassium‐Competitive Acid Blocker Vonoprazan

(2021) Darcy J. Mulford et al.   Clinical Pharmacology in Drug Development

Drug–Drug Interaction between Tacrolimus and Vonoprazan in Kidney Transplant Recipients

(2021) Yoshiharu Suzuki et al.   Journal of Clinical Medicine

Randomized clinical trial: 7‐day vonoprazan‐based versus 14‐day omeprazole‐based triple therapy for Helicobacter pylori

(2021) Chalermrat Bunchorntavakul et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis

(2020) Satoshi Shinozaki et al.   DIGESTION

Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan

(2020) Sho Suzuki et al.   GUT

Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo

(2020) Yiran Wang et al.   Frontiers in Pharmacology

Clinical impact of vonoprazan-based dual therapy with amoxicillin for H. pylori infection in a treatment-naïve cohort of junior high school students in Japan

(2020) Takuji Gotoda et al.   JOURNAL OF GASTROENTEROLOGY

Effect of Antibiotic Susceptibility and CYP3A4/5 and CYP2C19 Genotype on the Outcome of Vonoprazan-Containing Helicobacter pylori Eradication Therapy

(2020) Mitsushige Sugimoto et al.   Antibiotics-Basel

Recent Developments Pertaining to H. pylori Infection

(2020) Colin W. Howden et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori

(2019) Yoshimasa Saito et al.   Cancers

Cost‐effectiveness analysis and effectiveness of pharmacist‐managed outpatient clinics in Helicobacter pylori eradication therapy

(2019) Takayuki Seko et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease

(2019) Carmelo Scarpignato et al.   CURRENT OPINION IN GASTROENTEROLOGY

Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance?

(2019) Sho Suzuki et al.   WORLD JOURNAL OF GASTROENTEROLOGY

A Triple-Drug Blister-Packaged Drug with Vonoprazan Improves First-Line Eradication of Helicobacter pylori in Elderly Patients: A Retrospective Propensity Score-Matched Cohort Study

(2019) Tsutomu Nishida et al.   DIGESTION

Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori

(2019) Takahisa Furuta et al.   DIGESTION

Optimizing proton pump inhibitors in Helicobacter pylori treatment: Old and new tricks to improve effectiveness

(2019) Enzo Ierardi et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Efficacy of Vonoprazan for Helicobacter pylori Eradication

(2019) Shu Kiyotoki et al.   INTERNAL MEDICINE

Prevalence of antibiotic resistance in Helicobacter pylori : a systematic review and meta-analysis in World Health Organization regions

(2018) Alessia Savoldi et al.   GASTROENTEROLOGY

Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori

(2018) Min Li et al.   HELICOBACTER

Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication

(2018) Hiroki Tanabe et al.   Annals of Clinical Microbiology and Antimicrobials

Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date

(2018) Kentaro Sugano   Therapeutic Advances in Gastroenterology

Smoking and Drinking Did Not Increase the Failure of Therapeutic Helicobacter pylori Eradication by Vonoprazan, Clarithromycin, and Amoxicillin

(2018) Yoshimichi Takara et al.   DIGESTION

Helicobacter pylori and extragastric diseases: A review

(2018) Antonietta Gerarda Gravina et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin

(2017) Takahiro Suzuki et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori : A multicenter, prospective, randomized trial

(2017) Soichiro Sue et al.   HELICOBACTER

The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication

(2017) Soichiro Sue et al.   INTERNAL MEDICINE

Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection

(2017) Toshihiro Nishizawa et al.   JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION

Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy

(2017) Kouichi Sakurai et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-LineHelicobacter pyloriEradication: A Randomized Controlled Trial

(2017) Masafumi Maruyama et al.   Canadian Journal of Gastroenterology and Hepatology

The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy

(2016) Sho Suzuki et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori

(2016) Masahiro Tsujimae et al.   DIGESTION

Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance

(2016) Hiroshi Matsumoto et al.   DIGESTIVE DISEASES AND SCIENCES

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

(2016) Kazunari Murakami et al.   GUT

Vonoprazanversusconventional proton pump inhibitor-based triple therapy as first-line treatment againstHelicobacter pylori: A multicenter retrospective study in clinical practice

(2016) Satoki Shichijo et al.   Journal of Digestive Diseases

A novel potassium-competitive acid blocker improves the efficacy of clarithromycin-containing 7-day triple therapy against Helicobacter pylori

(2016)   Journal of Gastrointestinal and Liver Diseases

Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori

(2016) Satoshi Shinozaki et al.   KAOHSIUNG JOURNAL OF MEDICAL SCIENCES

The binding selectivity of vonoprazan (TAK-438) to the gastric H+,K+-ATPase

(2015) D. R. Scott et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects

(2015) H. Jenkins et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations

(2015) Hirotoshi Echizen   CLINICAL PHARMACOKINETICS

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

(2015) Yuuichi Sakurai et al.   Clinical and Translational Gastroenterology

Perils and pitfalls of long-term effects of proton pump inhibitors

(2013) Sheila M Wilhelm et al.   Expert Review of Clinical Pharmacology

Helicobacter pylori treatment in the era of increasing antibiotic resistance

(2010) D. Y. Graham et al.   GUT

Guidelines for the Management ofHelicobacter pyloriInfection in Japan: 2009 Revised Edition

(2010) Masahiro Asaka et al.   HELICOBACTER

1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases

(2010) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS